Arrowhead Pharmaceuticals, Inc. has announced the commencement of a Phase 1/2a clinical trial for ARO-ALK7, an investigational RNA interference (RNAi) therapeutic aimed at treating obesity. This study marks the first clinical evaluation of an RNAi therapeutic targeting a gene expressed in adipose tissue. The trial will explore the effects of single and multiple escalating doses of ARO-ALK7 as monotherapy in otherwise healthy obese subjects. Additionally, the trial will investigate the combination of ARO-ALK7 with tirzepatide in obese patients, both with and without type 2 diabetes. Preclinical studies of ARO-ALK7 demonstrated reduced body weight and fat mass while preserving lean muscle, through the silencing of Activin receptor-like kinase 7 (ALK7) expression in adipose tissue. Arrowhead's proprietary Targeted RNAi Molecule (TRiM™) platform facilitates the delivery of siRNA to multiple tissues and cell types, underscoring the company's leadership in this area.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.